Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-19T10:38:38.476Z Has data issue: false hasContentIssue false
  • English
  • Français

Neurorobiology and Evidence-Based Biological Treatments for Substance Abuse Disorders

Published online by Cambridge University Press:  07 November 2014

Iliyan S. Ivanov ,
Kurt P. Schuiz ,
Robyn C. Palmero  and
Jeffrey H. Newcorn
Get access Rights & Permissions [Opens in a new window]

Abstract

Behavioral patterns of addiction include compulsive drug-seeking, persistent abuse of substances despite the often dire consequences on social functioning and physical health, and the high probability of relapse even after prolonged drug-free periods.The recent focus on the biological basis of addiction has provided evidence to support the hypothesis that behavioral manifestations for addiction are influenced by biological factors, and biological factors often produce behavioral changes that can further increase risk. The current understanding of the role of the dopaminergic, glutamatergic, γ-aminobutyric acidergic, and opioid receptor systems in the pathophysiology of addiction as well as the clinical implications of these systems for new and emerging treatments will be discussed. This article will also review the pharmacologic agents used in the treatment of substance abuse disorders and presents evidence-based data for their safety, efficacy, and feasibility of use in different patient populations.

Type
Review Article
Information
CNS Spectrums , Volume 11 , Issue 11 , November 2006 , pp. 864 - 877
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Baldessarini, RJ, Tarazi, FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry. 1996;3:301–325.Google Scholar
2. Koob, GF, Le Moal, M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52–58.Google Scholar
3. Lubman, DI, Yucel, M, Pantelis, C. Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction. 2004;99:1491–1502.Google Scholar
4. Robinson, TE, Berridge, KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18:247–291.Google Scholar
5. Robinson, TE, Berridge, KC. The psychology and neurobiology of addiction: an incentivesensitization view. Addiction. 2000;95(suppl 2):S91–S117.Google Scholar
6. Winger, G, Woods, JH, Galuska, CM, Wade-Galuska, T. Behavioral perspectives on the neuroscience of drug addiction. J Exp Anal Behav. 2005;84:667–681.Google Scholar
7. Aron, AR, Robbins, TW, Poldrack, RA. Inhibition and the right inferior frontal cortex. Trends Cogn Sci. 2004;8:170–177.Google Scholar
8. McClure, SM, Laibson, DI, Loewenstein, G, Cohen, JD. Separate neural systems value immediate and delayed monetary rewards. Science. 2004;306:503–507.Google Scholar
9. Nigg, JT. Response inhibition and disruptive behaviors: toward a multiprocess conception of etiological heterogeneity for ADHD combined type and conduct disorder early-onset type. Ann N Y Acad Sci. 2003;1008:170–182.Google Scholar
10. Sonuga-Barke, EJ. The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev. 2003;27:593–604.Google Scholar
11. Johnson, SW, North, RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12:483–488.Google Scholar
12. Ritz, MC, Lamb, RJ, Goldberg, SR, Kuhar, MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219–1223.Google Scholar
13. Volkow, ND, Ding, YS, Fowler, JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52:456–463.Google Scholar
14. Di Chiara, G. Alcohol and dopamine. Alcohol Health Res World. 1997;21:108–114.Google Scholar
15. Dackis, CA, Gold, MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev. 1985;9:469–477.Google Scholar
16. Salamone, JD, Cousins, MS, Snyder, BJ. Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev. 1997;21:341–359.Google Scholar
17. Berridge, KC, Robinson, TE. Parsing reward. Trends Neurosci. 2003;26:507–513.Google Scholar
18. Di Chiara, G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol. 1998;12:54–67.Google Scholar
19. Schultz, W. Getting formal with dopamine and reward. Neuron. 2002;36:241–263.Google Scholar
20. Self, DW, Nestler, EJ. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend. 1998;51:49–60.Google Scholar
21. Self, DW. Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system. Neuropharmacology. 2004;47(suppl 1):242–255.Google Scholar
22. Garavan, H, Pankiewicz, J, Bloom, A, et al. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry. 2000;157:1789–1798.Google Scholar
23. Martin-Soelch, C, Chevalley, AF, Kunig, G, et al. Changes in reward-induced brain activation in opiate addicts. Eur J Neurosci. 2001;14:1360–1368.Google Scholar
24. Drevets, WC, Gautier, C, Price, JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry. 2001;49:81–96.Google Scholar
25. Volkow, ND, Wang, G, Fowler, JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.Google Scholar
26. Volkow, ND, Wang, GJ, Fowler, JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002;43:181–187.Google Scholar
27. Boileau, I, Assaad, JM, Pihl, RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse. 2003;49:226–231.Google Scholar
28. Volkow, ND, Fowler, JS, Wang, GJ, Swanson, JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9:557–569.Google Scholar
29. Volkow, ND, Wang, GJ, Fowler, JS, et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse. 2002;46:79–82.Google Scholar
30. Schilstrom, B, Svensson, HM, Svensson, TH, Nomikos, GG. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience. 1998;85:1005–1009.Google Scholar
31. Koob, GF. Cocaine reward and dopamine receptors: love at first site. Arch Gen Psychiatry. 1999;56:1107–1108.Google Scholar
32. Wise, RA. Opiate reward: sites and substrates. Neurosci Biobehav Rev. 1989;13:129–133.Google Scholar
33. Yim, HJ, Gonzales, RA. Ethanol-induced increases in dopamine extracellular concentration in rat nucleus accumbens are accounted for by increased release and not uptake inhibition. Alcohol. 2000;22:107–115.Google Scholar
34. Pich, EM, Pagliusi, SR, Tessari, M, Talabot-Ayer, D, Hooftvan Huijsduijnen, R, Chiamulera, C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 1997;275:83–86.Google Scholar
35. Maisonneuve, IM, Kreek, MJ. Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: an in vivo microdialysis study. J Pharmacol Exp Ther. 1994;268:916–921.Google Scholar
36. Mill, J, Asherson, P, Browes, C, D'Souza, U, Craig, I. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet. 2002;114:975–979.Google Scholar
37. Haertzen, CA, Kocher, TR, Miyasato, K. Reinforcements from the first drug experience can predict later drug habits and/or addiction: results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine. Drug Alcohol Depend. 1983;11:147–165.Google Scholar
38. Lott, DC, Kim, SJ, Cook, EH Jr, de Wit, H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005;30:602–609.Google Scholar
39. Warsi, M, Sattar, SP, Bhatia, SC, Petty, F. Aripiprazole reduces alcohol use. Can J Psychiatry. 2005;50:244.Google Scholar
40. Beresford, TP, Clapp, L, Martin, B, Wiberg, JL, Alters, J, Beresford, HF. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol. 2005;25:363–366.Google Scholar
41. Steele, C. Zyban: an effective treatment for nicotine addiction. Hosp Med. 2000;61:785–788.Google Scholar
42. White, WD, Crockford, D, Patten, S, El-Guebaly, N. A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res. 2005;7:809–813.Google Scholar
43. Montoya, ID, Preston, KL, Rothman, R, Gorelick, DA. Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. Am J Drug Alcohol Abuse. 2002;28:189–196.Google Scholar
44. Chan-Ob, T, Kuntawongse, N, Boonyanaruthee, V. Bupropion for amphetamine withdrawal syndrome. J Med Assoc Thai. 2001;84:1763–1765.Google Scholar
45. Solhkhah, R, Wilens, TE, Daly, J, Prince, JB, Van Patten, SL, Biederman, J. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol. 2005;15:777–786.Google Scholar
46. Gorelick, DA, Gardner, EL, Xi, ZX. Agents in development for the management of cocaine abuse. Drugs. 2004;64:1547–1573.Google Scholar
47. Mayer, P, Hollt, V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics. 2006;16:1–7.Google Scholar
48. Fattore, L, Cossu, G, Spano, MS, et al. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol. 2004;16:147–158.Google Scholar
49. Ciccocioppo, R, Economidou, D, Fedeli, A, et al. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl). 2004;172:170–178.Google Scholar
50. Kuzmin, A, Kreek, MJ, Bakalkin, G, Liljequist, S. The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology. In press.Google Scholar
51. Ghozland, S, Matthes, HW, Simonin, F, Filliol, D, Kieffer, BL, Maldonado, R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci. 2002;22:1146–1154.Google Scholar
52. Tao, R, Auerbach, SB. Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience. 1995;68:553–561.Google Scholar
53. Kalyuzhny, AE, Wessendorf, MW. Relationship of mu- and delta-opioid receptors to GABAergic neurons in the central nervous system, including antinociceptive brainstem circuits. J Comp Neurol. 1998;392:528–547.Google Scholar
54. Mansour, A, Watson, SJ, Akil, H. Opioid receptors: past, present and future. Trends Neurosci. 1995;18:69–70.Google Scholar
55. Martin-Schild, S, Gerall, AA, Kastin, AJ, Zadina, JE. Differential distribution of endomorphin 1- and endomorphin 2-like immunoreactivities in the CNS of the rodent. J Comp Neurol. 1999;405:450–471.Google Scholar
56. Tork, I. Anatomy of the serotonergic system. Ann N Y Acad Sci. 1990;600:9–34.Google Scholar
57. Benloucif, S, Keegan, MJ, Galloway, MP. Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther. 1993;265:373–377.Google Scholar
58. Guan, XM, McBride, WJ. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull. 1989;23:541–547.Google Scholar
59. Rocha, BA, Fumagalli, F, Gainetdinov, RR, et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci. 1998;1:132–137.Google Scholar
60. Uhl, GR, Hall, FS, Sora, I. Cocaine, reward, movement and monoamine transporters. Mol Psychiatry. 2002;7:21–26.Google Scholar
61. Weiss, F, Mitchiner, M, Bloom, FE, Koob, GF. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology (Berl). 1990;101:178–186.Google Scholar
62. Haigler, HJ. Morphine: effects on serotonergic neurons and neurons in areas with a serotonergic input. Eur J Pharmacol. 1978;51:361–376.Google Scholar
63. Jolas, T, Aghajanian, GK. Neurotensin and the serotonergic system. Prog Neurobiol. 1997;52:455–468.Google Scholar
64. Tao, R, Auerbach, SB. Increased extracellular serotonin in rat brain after systemic or intraraphe administration of morphine. J Neurochem. 1994;63:517–524.Google Scholar
65. Tao, R, Ma, Z, Auerbach, SB. Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin. J Pharmacol Exp Ther. 2000;294:571–579.Google Scholar
66. Altshuler, HL, Phillips, PE, Feinhandler, DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980;26:679–688.Google Scholar
67. Altshuler, HL. Behavioral methods for the assessment of alcohol tolerance and dependence. Drug Alcohol Depend. 1979;4:333–346.Google Scholar
68. Farre, M, Mas, A, Torrens, M, Moreno, V, Cami, J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. 2002;65:283–290.Google Scholar
69. Glanz, M, Klawansky, S, McAullife, W, Chalmers, T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials. Am J Addict. 1997;6:339–349.Google Scholar
70. Kreek, MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186–216.Google Scholar
71. Green, H, James, RA, Gilbert, JD, Harpas, P, Byard, RW. Methadone maintenance programs-a two-edged sword? Am J Forensic Med Pathol. 2000;21:359–361.Google Scholar
72. Musshoff, F, Lachenmeier, DW, Madea, B. Methadone substitution: medicolegal problems in Germany. Forensic Sci Int. 2003;133:118–124.Google Scholar
73. Pearson, EC, Woosley, RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747–753.Google Scholar
74. Fiellin, DA, Pantalon, MV, Chawarski, MC, et al. Counseling plus buprenorphine-nalox-one maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365–374.Google Scholar
75. Ebner, R, Schreiber, W, Zierer, C. Buprenorphine or methadone for detoxification of young opioid addicts? [German]. Psychiatr Prax. 2004;31(suppl 1):S108–S110.Google Scholar
76. Marsch, LA, Bickel, WK, Badger, GJ, Stothart, ME, Quesnel, KJ, Stanger, C, Brooklyn, J. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62:1157–1164.Google Scholar
77. Verrando, R, Robaeys, G, Mathei, C, Buntinx, F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastroenterol Belg. 2005;68:81–85.Google Scholar
78. Raistrick, D, West, D, Finnegan, O, Thistlethwaite, G, Brearley, R, Banbery, J. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial. Addiction. 2005;100:1860–1867.Google Scholar
79. Harris, AH, Gospodarevskaya, E, Ritter, AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005;23:77–91.Google Scholar
80. Digiusto, E, Lintzeris, N, Breen, C, et al. Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addict Behav. 2005;30:443–456.Google Scholar
81. Cook, S, Indig, D, Gray, J, McGrath, D. Opiate overdose and health treatment options for opiate users in New South Wales, 1999-2002. NSW Public Health Bull. 2004;15:125–131.Google Scholar
82. Simoens, S, Matheson, C, Bond, C, Inkster, K, Ludbrook, A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005;55:139–146.Google Scholar
83. Doran, CM, Shanahan, M, Bell, J, Gibson, A. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug Alcohol Rev. 2004;23:171–175.Google Scholar
84. Latt, NC, Jurd, S, Houseman, J, Wutzke, SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176:530–534.Google Scholar
85. Morris, PL, Hopwood, M, Whelan, G, Gardiner, J, Drummond, E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96:1565–1573.Google Scholar
86. O'Malley, SS, Rounsaville, BJ, Farren, C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med. 2003;163:1695–1704.Google Scholar
87. Deas, D, May, MP, Randall, C, Johnson, N, Anton, R. Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol. 2005;15:723–728.Google Scholar
88. Roozen, HG, de Waart, R, van der Windt, DA, van den Brink, W, de Jong, CA, Kerkhof, AJ. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol. 2006;16:311–323.Google Scholar
89. Krystal, JH, Cramer, JA, Krol, WF, Kirk, GF, Rosenheck, RA and the Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734–1739.Google Scholar
90. West, SL, Garbutt, JC, Carey, TS, et al. Pharmacotherapy for alcohol dependence. Evid Rep Technol Assess (Summ). 1999;(3):1–5.Google Scholar
91. Feeney, GF, Connor, JP, Young, RM, Tucker, J, McPherson, A. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006;41:321–327.Google Scholar
92. Anton, RF, O'Malley, SS, Ciraulo, DA, et al, and COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–2017.Google Scholar
93. Anton, RF, Swift, RM. Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict. 2003;12(suppl 1):S53–S68.Google Scholar
94. Kiefer, F, Wiedemann, K. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol. 2004;39:542–547.Google Scholar
95. Williams, SH. Medications for treating alcohol dependence. Am Fam Physician. 2005;72:1775–1780.Google Scholar
96. Johnson, BA. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin Pharmacother. 2006;7:1065–1073.Google Scholar
97. Mason, BJ, Salvato, FR, Williams, LD, Ritvo, EC, Cutler, RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719–724.Google Scholar
98. Ozawa, H, Takashima, S. Immunocytochemical development of transferrin and ferritin immunoreactivity in the human pons and cerebellum. J Child Neurol. 1998;13:59–63.Google Scholar
99. Wilson, MA, Tonegawa, S. Synaptic plasticity, place cells and spatial memory: study with second generation knockouts. Trends Neurosci. 1997;20:102–106.Google Scholar
100. Ferry, B, Magistretti, PJ, Pralong, E. High potency of the orally-active NMDA-receptor antagonist CGP 40 116 in inhibiting excitatory postsynaptic potentials of rat basolateral amygdala neurones in vitro. Neuropharmacology. 1997;36:1555–1559.Google Scholar
101. Bardo, MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol. 1998;12:37–67.Google Scholar
102. Koob, GF, Weiss, F. Neuropharmacology of cocaine and ethanol dependence. Recent Dev Alcohol. 1992;10:201–233.Google Scholar
103. Mogenson, GJ, Wu, M, Jones, DL. Locomotor activity elicited by injections of picrotoxin into the ventral tegmental area is attenuated by injections of GABA into fhe globus pallidus. Brain Res. 1980;191:569–571.Google Scholar
104. Mulder, AB, Nordquist, RE, Orgut, O, Pennartz, CM. Learning-related changes in response patterns of prefrontal neurons during instrumental conditioning. Behav Brain Res. 2003;146:77–88.Google Scholar
105. Floresco, SB, Grace, AA. Gating of hippocampal-evoked activity in prefrontal cortical neurons by inputs from the mediodorsal thalamus and ventral tegmental area. J Neurosci. 2003;23:3930–3943.Google Scholar
106. Bast, T, Feldon, J. Hippocampal modulation of sensorimotor processes. Prog Neurobiol. 2003;70:319–345.Google Scholar
107. Legault, M, Congar, P, Michel, FJ, Trudeau, LE. Presynaptic action of neurotensin on cultured ventral tegmental area dopaminergic neurones. Neuroscience. 2002;111:177–187.Google Scholar
108. Vorel, SR, Liu, X, Hayes, RJ, Spector, JA, Gardner, EL. Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science. 2001;292:1175–1178.Google Scholar
109. Yang, CR, Mogenson, GJ. Ventral pallidal neuronal responses to dopamine receptor stimulation in the nucleus accumbens. Brain Res. 1989;489:237–246.Google Scholar
110. Swerdlow, NR, Braff, DL, Geyer, MA. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Res. 1990;532:146–150.Google Scholar
111. Pittaluga, A, Feligioni, M, Ghersi, C, Gemignani, A, Raiteri, M. Potentiation of NMDA receptor function through somatostatin release: a possible mechanism for the cognition-enhancing activity of GABA(B) receptor antagonists. Neuropharmacology. 2001;41:301–310.Google Scholar
112. Pittaluga, A, Pattarini, R, Feligioni, M, Raiteri, M. N-methyl-D-aspartate receptors mediating hippocampal noradrenaline and striatal dopamine release display differential sensitivity to quinolinic acid, the HIV-1 envelope protein gp120, external pH and protein kinase C inhibition. J Neurochem. 2001;76:139–148.Google Scholar
113. Chiamulera, C, Epping-Jordan, MP, Zocchi, A, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 2001;4:873–874.Google Scholar
114. Druhan, JP, Wilent, WB. Effects of the competitive N-methyl-D-aspartate receptor antagonist, CPP, on the development and expression of conditioned hyperactivity and sensitization induced by cocaine. Behav Brain Res. 1999;102:195–210.Google Scholar
115. Mathe, JM, Nomikos, GG, Schilstrom, B, Svensson, TH. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res. 1998;51:583–592.Google Scholar
116. Takahata, R, Moghaddam, B. Target-specific glutamatergic regulation of dopamine neurons in the ventral tegmental area. J Neurochem. 2000;75:1775–1778.Google Scholar
117. Tsai, G, Coyle, JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998;49:173–184.Google Scholar
118. Tsai, G, Gastfriend, DR, Coyle, JT. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995;152:332–340.Google Scholar
119. Mason, BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62(suppl 20):42–48.Google Scholar
120. Ait-Daoud, N, Malcolm, RJ Jr, Johnson, BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav. 2006;31:1628–1649.Google Scholar
121. Johnson, BA, Ait-Daoud, N, Bowden, CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–1685.Google Scholar
122. Johnson, BA, Ait-Daoud, N, Akhtar, FZ, Javors, MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165:1600–1605.Google Scholar
123. Whiting, PJ. The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003;6:648–657.Google Scholar
124. Somogyi, P, Tamas, G, Lujan, R, Buhl, EH. Salient features of synaptic organisation in the cerebral cortex. Brain Res Brain Res Rev. 1998;26:113–135.Google Scholar
125. Squires, RF, Benson, DI, Braestrup, C, et al. Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol Biochem Behav. 1979;10:825–830.Google Scholar
126. Squires, RF, Brastrup, C. Benzodiazepine receptors in rat brain. Nature. 1977;266:732–734.Google Scholar
127. Whiting, PJ. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today. 2003;8:445–450.Google Scholar
128. Ator, N. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr. 2005;10:31–39.Google Scholar
129. Bettler, B, Kaupmann, K, Bowery, N. GABAB receptors: drugs meet clones. Curr Opin Neurobiol. 1998;8:345–350.Google Scholar
130. Kaupmann, K, Huggel, K, Heid, J, et al. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997;386:239–246.Google Scholar
131. Dawson, GR, Collinson, N, Atack, JR. Development of subtype selective GABAA modulators. CNS Spectr. 2005;10:21–27.Google Scholar
132. Koob, GF. A role for GABA mechanisms in the motivational effects of alcohol. Biochem Pharmacol. 2004;68:1515–1525.Google Scholar
133. Heimer, L, Alheid, GF. Piecing together the puzzle of basal forebrain anatomy. Adv Exp Med Biol. 1991;295:1–42.Google Scholar
134. Koob, GF, Roberts, AJ, Schulteis, G, et al. Neurocircuitry targets in ethanoi reward and dependence. Alcohol Clin Exp Res. 1998;22:3–9.Google Scholar
135. Grobin, AC, Matthews, DB, Devaud, LL, Morrow, AL. The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl). 1998;139:2–19.Google Scholar
136. Hajak, G, Muller, WE, Wittchen, HU, Pittrow, D, Kirch, W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98:1371–1378.Google Scholar
137. Lhuillier, L, Mombereau, C, Cryan, JF, Kaupmann, K. GABA(B) receptor-positive modulation decreases selective molecular and behavioral effects of cocaine. Neuropsychopharmacology. In press.Google Scholar
138. Slattery, DA, Markou, A, Froestl, W, Cryan, JF. The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology. 2005;30:2065–2072.Google Scholar
139. Weerts, EM, Froestl, W, Griffiths, RR. Effects of GABAergic modulators on food and cocaine self-administration in baboons. Drug Alcohol Depend. 2005;80:369–376.Google Scholar
140. Haney, M, Hart, CL, Foltin, RW. Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology. 2006;31:1814–1821.Google Scholar
141. Shoptaw, S, Yang, X, Rotheram-Fuller, EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003;64:1440–1448.Google Scholar
142. Assadi, SM, Radgoodarzi, R, Ahmadi-Abhari, SA. Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]. BMC Psychiatry. 2003;3:16.Google Scholar
143. Gardner, EL, Schiffer, WK, Horan, BA, et al. Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats. Synapse. 2002;46:240–250.Google Scholar
144. Stromberg, MF, Mackler, SA, Volpicelli, JR, O'Brien, CP, Dewey, SL. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanoi in the rat. Pharmacol Biochem Behav. 2001;68:291–299.Google Scholar
145. Brodie, JD, Figueroa, E, Laska, EM, Dewey, SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55:122–125.Google Scholar